Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.

BMC Dermatol 2018 10 25;18(1). Epub 2018 Oct 25.

Respiralab, Respiralab Research Group, Guayaquil, Ecuador.

Background: Despite the current knowledge of UV, there is a lack of consensus among diagnostic criteria and management. In general, antihistamine therapy is regularly used for the symptomatic management of pruritus but does not control inflammation or alter the course of the disease. Monoclonal antibodies such as omalizumab (anti-IgE) have been proposed as a potential treatment for urticarial vasculitis. A few studies have reported the benefits of omalizumab in patient-reported outcome measures (PROMs). Herein we describe a female patient with urticarial vasculitis who was treated with omalizumab. We discuss the response to treatment and possible implications of PROMs in guiding the management of the disease.

Case Presentation: We describe the case of a 57-year-old woman with a diagnosis of urticarial vasculitis. Due to lack of response to first-line treatment and the severity of the disease, treatment with omalizumab was initiated. Omalizumab 150 mg was administered every four weeks for three months. Second-generation antihistamines were used as needed. Both CU-Q2oL and UAS 7 improved. After three-month therapy with omalizumab, disease severity improved from moderate severity (UAS7 = 19) to well controlled (UAS7 = 6). However, 5 months after the last administration of omalizumab, the patient complained of worsening symptoms and active disease with quality of life impairment. A single dose of omalizumab (150 mg) was prescribed with corticosteroids. Thereafter, the patient presented a disease activity and quality of life with a fluctuating pattern that was controlled with additional doses of omalizumab.

Conclusion: In chronic urticaria, patient-reported outcome measures (PROMs) are important for assessing disease status and the impact of symptoms on patients' lives. However, to our knowledge, there is no validated tool to measure such outcomes in UV patients. Although UAS7 and CU-Q2oL were not designed for UV assessment, they might be useful in the clinical setting as objective measures to determine treatment efficacy. However, some domains in the CU-Q2oL questionnaires do not correlate well with UAS7, which might serve as a relative indication to continue treatment despite disease severity improvement. Based on our observations, we believe omalizumab 150 mg might be a feasible therapeutic alternative when first-line treatment is unsuccessful.

Download full-text PDF

Publisher Site Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
October 2018
30 Reads

Publication Analysis

Top Keywords

urticarial vasculitis
omalizumab 150 mg
treated omalizumab
measures proms
vasculitis treated
disease severity
quality life
first-line treatment
patient-reported outcome
outcome measures
5 months administration
uas7 = 6 5 months
worsening symptoms
complained worsening
administration omalizumab
symptoms active
omalizumab patient


(Supplied by CrossRef)
Article in Br Med J (Clin Res Ed)
RP Warin et al.
Br Med J (Clin Res Ed) 1983
Article in Curr Opin Rheumatol
JJ Wisnieski et al.
Curr Opin Rheumatol 2000
Article in Clin Exp Dermatol
AK Black et al.
Clin Exp Dermatol 1996
Article in Br J Dermatol
RR Jones et al.
Br J Dermatol 1983
Article in Immunol Allergy Clin N Am
MD Davis et al.
Immunol Allergy Clin N Am 2004
Article in World Allergy Organ J
I Cherrez Ojeda et al.
World Allergy Organ J 2018
Article in Allergy Asthma Proc
S Chang et al.
Allergy Asthma Proc 2007
Article in Arthritis Rheumatol
M Jachiet et al.
Arthritis Rheumatol 2015
Article in Clin Exp Dermatol
C Tosoni et al.
Clin Exp Dermatol 2009
Article in J Clin Aesthet Dermatol
A Buck et al.
J Clin Aesthet Dermatol 2012
Article in J Am Acad Dermatol
DR Mehregan et al.
J Am Acad Dermatol 1992

Similar Publications